Your Breath as a Diagnostic Tool: Smell Tests That Might Detect Cancer or Infection

The Emerging Science of Breath Analysis

For decades, doctors have relied on invasive tests, imaging, and bloodwork to diagnose disease. Now, breath analysis is emerging as a non-invasive, rapid diagnostic tool with the potential to transform healthcare. Every exhalation carries volatile organic compounds (VOCs), small molecules produced by metabolic processes in the body. Research has shown that patterns of these compounds can serve as biomarkers for disease, offering insights into cancer, infections, and even metabolic disorders.

Breath Tests and Cancer Detection

One of the most promising applications of breath analysis is in early cancer detection. For example, a 2022 study published in Science Direct analyzed 16 VOCs in the breath of patients and reported an area under the curve (AUC) of 0.952, with sensitivity of 89.2% and specificity of 89.1% for lung cancer detection. Early detection is critical: lung cancer remains the leading cause of cancer death worldwide, with over 1.8 million deaths annually.

In the United Kingdom, the NHS is launching a large-scale clinical trial in 2025 using a breath test capable of identifying liver, pancreatic, and esophageal cancers. These cancers collectively account for nearly 44,000 deaths per year in the UK. The test provides results in days rather than weeks, representing a faster, non-invasive alternative to biopsies and imaging. 

Other research has shown that breath tests may detect colorectal cancer and gastric cancer with up to 90% accuracy, providing a promising supplement to traditional screening methods like colonoscopies and endoscopies.

Detecting Infections Through Breath

Breath analysis is also proving useful in diagnosing infections. The urea breath test (UBT) is a gold standard for detecting Helicobacter pylori, a bacterium responsible for gastric ulcers and increasing the risk of stomach cancer. Meta-analyses report that UBT has a sensitivity of 96% and specificity of 93%, making it both reliable and non-invasive.

More recently, the FDA approved the InspectIR COVID-19 Breathalyzer, which detects chemical compounds associated with SARS-CoV-2 in exhaled breath. This device provides results in approximately three minutes and can be used in clinics, testing sites, and other public settings, highlighting how breath analysis can accelerate infection detection and containment. 

Mechanisms Behind Breath Diagnostics

The underlying principle of breath-based diagnostics lies in detecting the unique chemical signatures that diseases produce. Cancer cells, for example, often have altered metabolic pathways, producing VOCs such as aldehydes, ketones, and hydrocarbons that are released into the bloodstream and eventually exhaled. Similarly, bacterial or viral infections generate specific metabolic byproducts detectable in breath.

Advances in sensor technology, machine learning, and nanotechnology have enabled devices to detect VOCs at parts-per-billion concentrations, greatly increasing diagnostic sensitivity. Breathalyzers, mass spectrometry devices, and nanoarray sensors are being refined to differentiate between complex patterns of VOCs associated with different diseases.

Challenges and Limitations

Despite promising results, breath diagnostics are still in development. VOC profiles can vary depending on diet, lifestyle, environment, and coexisting health conditions, which may affect accuracy. Large-scale validation studies across diverse populations are needed to standardize diagnostic thresholds and ensure reliability. Additionally, regulatory approval and clinical adoption require rigorous testing and reproducibility.

The Future of Breath-Based Medicine

The potential applications of breath diagnostics extend far beyond cancer and infection. Researchers are exploring their use in detecting metabolic disorders like diabetes, monitoring liver function, diagnosing gastrointestinal conditions, and even tracking neurodegenerative diseases such as Alzheimer’s.

The market for breath-based diagnostics is projected to grow rapidly, driven by demand for non-invasive, rapid, and cost-effective screening tools. Industry analysts predict that the global breath analysis market could exceed $8 billion by 2030, with cancer and infection detection leading adoption.

Conclusion

Breath analysis represents a revolutionary frontier in medical diagnostics. By detecting diseases early through the chemicals present in exhaled air, clinicians may intervene sooner, improve outcomes, and reduce reliance on invasive procedures. Although challenges remain, ongoing clinical trials and technological innovations suggest that our breath could become a key tool in precision medicine, transforming the way we detect and manage disease.